8-K - Artelo Biosciences, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Artelo Biosciences, Inc. filed a Certificate of Change on March 5, 2026, to effect a 1-for-3 reverse stock split of its common stock, effective March 10, 2026, reducing outstanding shares from 2,124,772 to approximately 708,258 and authorized common shares from 500,000,000 to 166,666,667 to improve marketability and liquidity.

Key Takeaways

1Reverse Split ratio: 1-for-3 (every 3 pre-split shares combine into 1 new share)

2Effective Time: 12:01 a.m. ET on March 10, 2026

3Pre-split outstanding Common Stock: 2,124,772 shares

4Post-split outstanding Common Stock: approximately 708,258 shares

5Pre-split authorized Common Stock: 500,000,000 shares; Post-split: 166,666,667 shares

6New CUSIP: 04301G706

7No fractional shares issued; fractional entitlements rounded up to 1 whole share

Current Report Details

Event Type

Securities Modification

Disclosure

Mandatory

Variant

8-K

Items Reported

3.03

. A copy of the Certificate of Change described in Item 5.03 is filed as Exhibit 3.1 to this Current Report on Form 8-K. Item 5.03. Amendments to Articles of In

Securities Modification

8.01

. Other Events. On March 6, 2026, the Company issued a press release announcing the Reverse Split. A copy of the press release is attached hereto as Exhibit 99.

Other Event

9.01

. Financial Statements and Exhibits (d) Exhibits. Exhibit No. Exhibit 3.1 Certificate of Change 99.1 Press Release 104 Cover Page Interactive Data File (embedde

Exhibits Only

Exhibits (3)

3.1

CERTIFICATE OF CHANGE

8-K

FORM 8-K

99.1

PRESS RELEASE